Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.

Abstract

Purpose The National Wilms Tumor Study (NWTS) treatment of favorable histology Wilms tumor with lung metastases was vincristine/dactinomycin/doxorubicin (DD4A) and lung radiation therapy (RT). The AREN0533 study applied a new risk stratification and treatment strategy to improve event-free survival (EFS) while reducing exposure to lung RT. Methods Patients with favorable histology Wilms tumor and isolated lung metastases showing complete lung nodule response (CR) after 6 weeks of DD4A continued receiving chemotherapy without lung RT. Patients with incomplete response (IR) or loss of heterozygosity at chromosomes 1p/16q received lung RT and four cycles of cyclophosphamide/etoposide in addition to DD4A drugs (Regimen M). AREN0533 was designed to preserve a 4-year EFS of 85% for lung nodule CR and improve 4-year EFS from 75% to 85% for lung nodule IR. Results Among 292 assessable patients, 133 had CR and 159 had IR. For patients with CR, 4-year EFS and overall survival (OS) estimates were 79.5% (95% CI, 71.2% to 87.8%) and 96.1% (95% CI, 92.1% to 100%), respectively. Expected versus observed event rates were 15% and 20.2% ( P = .052), respectively. For patients with IR, 4-year EFS and OS estimates were 88.5% (95% CI, 81.8% to 95.3%) and 95.4% (95% CI, 90.9% to 99.8%), respectively. Expected versus observed event rates were 25% and 12.2% ( P < .001), respectively. Overall, 4-year EFS and OS were 85.4% (95% CI, 80.5% to 90.2%) and 95.6% (95% CI, 92.8% to 98.4%) compared with 72.5% (95% CI, 66.9% to 78.1%; P < .001) and 84.0% (95% CI, 79.4% to 88.6%; P < .001), respectively, in the predecessor NWTS-5 study. Conclusion Excellent OS was achieved after omission of primary lung RT in patients with lung nodule CR, although there were more events than expected. EFS was significantly improved, with excellent OS, in patients with lung nodule IR using four cycles of cyclophosphamide/etoposide in addition to DD4A drugs. The overall AREN0533 treatment strategy yielded EFS and OS estimates that were superior to previous studies.

• Authors: David B Dix, Nita L Seibel, Yueh-Yun Chi, Geetika Khanna, Eric Gratias, James R Anderson, Elizabeth A Mullen, James I Geller, John A Kalapurakal, Arnold C Paulino, Elizabeth J Perlman, Peter F Ehrlich, Marcio Malogolowkin, Julie M Gastier-Foster, Elizabeth Wagner, Paul E Grundy, Conrad V Fernandez, Jeffrey S Dome
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 36 Issue 16 Pg. 1564-1570 (06 01 2018) ISSN: 1527-7755 [Electronic] United States
• PMID: 29659330 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• Dactinomycin
• Vincristine
• Etoposide
• Doxorubicin
• Cyclophosphamide

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers, Tumor
• Child
• Child, Preschool
• Cyclophosphamide (administration & dosage)
• Dactinomycin (administration & dosage)
• Doxorubicin (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Humans
• Lung Neoplasms (drug therapy, genetics, radiotherapy, secondary)
• Male
• Neoplasm Staging
• Risk Factors
• Survival Rate
• Treatment Outcome
• Vincristine (administration & dosage)
• Wilms Tumor (drug therapy, genetics, pathology)